<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377637</url>
  </required_header>
  <id_info>
    <org_study_id>WX17801</org_study_id>
    <nct_id>NCT00377637</nct_id>
    <nct_alias>NCT00121082</nct_alias>
  </id_info>
  <brief_title>A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.</brief_title>
  <official_title>A Prospective, Randomized, Active Controlled, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Mycophenolate Mofetil (MMF) in Inducing Response and Maintaining Remission in Subjects With Lupus Nephritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aspreva Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This 2 arm study assessed the efficacy of Mycophenolate Mofetil (MMF; CellCept) compared to
      cyclophosphamide in inducing a response in patients with lupus nephritis, and the long term
      efficacy of MMF compared to azathioprine in maintaining remission and renal function.
      Patients were randomized to receive either MMF (1.5 g twice daily [bid]) or cyclophosphamide
      (0.5-1.0 g/m^2 in monthly pulses) in the induction phase. Those patients meeting criteria for
      response were re-randomized for entry into the maintenance phase, to receive either MMF (1 g
      bid) or azathioprine (2 mg/kg/day).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction Phase: Number of Patients Showing Treatment Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Treatment response was adjudicated by a blinded clinical endpoints committee (CEC) and defined as: a) Decrease in proteinuria, defined as a decrease in the urine protein to creatinine ratio (UPCr) to &lt;3 in subjects with baseline proteinuria ≥3 UPCr or a decrease in the UPCr by ≥50% in subjects with proteinuria &lt;3 UPCr at Baseline, and b) Stabilization of serum creatinine or improvement. UPCr were derived from the 24 hour urine collection. Patients who did not show a treatment response at Week 24 or who withdrew earlier than Week 24 were considered non-responders.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance Phase: Kaplan-Meier Estimates of Percentage of Participants Treatment Failure Free, by Time Interval</measure>
    <time_frame>From the start of the Maintenance Phase to Month 36</time_frame>
    <description>Treatment Failure was adjudicated by a clinical endpoints committee and was defined as the time to the earliest occurrence of any one of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or a requirement for rescue therapy for exacerbation or deterioration of Lupus nephritis. Kaplan-Meier survival curves were estimated from the observed time to treatment failure for each patient. The data presented are the percentage of participants who were treatment-failure free at each time interval as estimated by Kaplan-Meier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Induction Phase: Number of Participants Achieving Complete Remission</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants achieving complete remission as defined by return to normal serum creatinine, proteinuria ≤500 mg/24 hours and an inactive urinary sediment (absence of red blood cells, white blood cells or cellular or granular casts) after 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Phase: Change From Baseline to Week 24 in Serum Creatinine</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Phase: Change From Baseline to Week 24 in 24-hour Urine Protein</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>24-hour urine protein was measured at Baseline and Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Phase: Change From Baseline to Week 24 in Serum Albumin</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Phase: Change in Renal British Isles Lupus Assessment Group (BILAG) Score</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>BILAG indices provide a scoring system for the assessment of lupus disease activity in terms of the need for steroid treatment in 8 organs/systems. Eighty-six items were scored resulting in a classification of A (severe activity), B (moderate activity), C (mild activity), D (no current activity) and E (no activity ever observed) for each organ system. The BILAG individual system summaries were calculated by a program supplied by ADS-Limathon (Sheffield, UK).
The score at baseline was compared to the score at the 24 week endpoint for each treatment group, reported here for the renal system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Phase: Change From Baseline in Short-Form Health Survey (SF-36) Domain and Component Scores</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The SF-36 is a 36 item quality of life questionnaire. The short-form version has eleven questions that permit the participant to rate how they feel that particular day. The SF-36 consists of eight scaled scores and two component scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 score with the higher scores indicating better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Deaths</measure>
    <time_frame>From the start of the Maintenance Phase to Month 36</time_frame>
    <description>Treatment Failure was adjudicated by a clinical endpoints committee (CEC) and was defined as the time to the earliest occurrence of any one of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or a requirement for rescue therapy for exacerbation or deterioration of Lupus nephritis (LN).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Participants With End-stage Renal Disease (ESRD)</measure>
    <time_frame>From the start of the Maintenance Phase to Month 36</time_frame>
    <description>Time to treatment failure, adjudicated by the Clinical Endpoints Committee (CEC), was defined as any 1 the following: death, ESRD, sustained doubling of serum creatinine, renal flare (proteinuric or nephritic), or requirement for rescue therapy to treat deterioration or exacerbation of Lupus nephritis. ESRD is defined as progression to chronic hemodialysis or renal transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Participants With Sustained Doubling of Serum Creatinine</measure>
    <time_frame>From the start of the Maintenance Phase to Month 36</time_frame>
    <description>Sustained doubling of serum creatinine concentration is defined as the first serum creatinine value that is twice the mean of the lowest 2 values from screening to end of induction, as confirmed by a second serum creatinine value obtained at least 4 weeks after the initial doubling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Events Contributing to the Primary Endpoint: Kaplan-Meier Estimates of Percentage of Participants Renal Flare Free, by Time Interval</measure>
    <time_frame>From the start of the Maintenance Phase to Month 36</time_frame>
    <description>A proteinuric flare is defined as a doubling of the urine protein:creatinine ratio, and proteinuria ≥1 g/24 h in patients with urine protein ≤0.5 g/24 h at the end of the induction phase, or proteinuria ≥2 g/24 h if urine protein was &gt;0.5 g/24 h at the end of the induction phase. A nephritic flare is defined as a 25% increase in serum creatinine accompanied by 1 or more of the following: (a) simultaneous doubling of the proteinuria reaching a minimum of 2 g/24 h (b) new/increased hematuria or (c) the appearance of cellular casts. All flares were adjudicated by a clinical endpoints committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Events Contributing to the Primary Endpoint: Kaplan-Meier Estimates of Percentage of Participants Not Receiving Rescue Therapy</measure>
    <time_frame>From the start of the Maintenance Phase to Month 36</time_frame>
    <description>The primary efficacy parameter was the time to treatment failure, adjudicated by the Clinical Endpoints Committee (CEC), defined as any of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or requirement for rescue therapy to treat deterioration or exacerbation of Lupus nephritis. Kaplan-Meier survival curves were estimated from the observed time to rescue treatment for each patient. The data presented are the percentage of participants who were rescue treatment free at each time interval as estimated by Kaplan-Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Participants With Major Extra-renal Flare</measure>
    <time_frame>From the start of the Maintenance Phase to Month 36</time_frame>
    <description>A major extra-renal flare is defined as a British Isles Lupus Assessment Group (BILAG) Score category A in one extrarenal organ or three organs with concurrent category B scores. BILAG indices provide a scoring system for the assessment of lupus disease activity in terms of the need for steroid treatment in 8 organs/systems. Eighty-six items were scored resulting in a classification of A (severe activity), B (moderate activity), C (mild activity), D (no current activity) and E (no activity ever observed) for each organ system.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Induction Phase: Mycophenolate mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24 weeks of the Induction Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Phase: Cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received monthly infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Phase: Mycophenolate mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Phase: Azathioprine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil (MMF)</intervention_name>
    <description>Supplied as 500 mg tablets taken orally twice a day (BID). Dose specific for each arm. Dosing started at 500 mg BID for the first week, increasing by 500 mg in subsequent weeks until the final target dose was reached.</description>
    <arm_group_label>Induction Phase: Mycophenolate mofetil</arm_group_label>
    <arm_group_label>Maintenance Phase: Mycophenolate mofetil</arm_group_label>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Intravenous cyclophosphamide (IVC) was administered every four weeks (monthly) to a total of six infusions.
Dosing was started at 0.75 g/m^2 of body surface area for the first month, with subsequent doses at 0.5-1.0 g/m^2. The target dose was 1.0 g/m^2, but doses were titrated by 0.25 g/m^2 increments to maintain nadir leukocyte count between 2500-4000/mm^3.</description>
    <arm_group_label>Induction Phase: Cyclophosphamide</arm_group_label>
    <other_name>Endoxan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <description>2 mg/kg/day orally, provided as 50 mg capsules to be taken after meals.</description>
    <arm_group_label>Maintenance Phase: Azathioprine</arm_group_label>
    <other_name>Imuran®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Azathioprine</intervention_name>
    <description>Placebo capsules matching Azathioprine taken orally once a day.</description>
    <arm_group_label>Maintenance Phase: Mycophenolate mofetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Mycophenolate mofetil</intervention_name>
    <description>Placebo tablets matching Mycophenolate mofetil taken orally twice daily.</description>
    <arm_group_label>Maintenance Phase: Azathioprine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.</description>
    <arm_group_label>Induction Phase: Mycophenolate mofetil</arm_group_label>
    <arm_group_label>Induction Phase: Cyclophosphamide</arm_group_label>
    <arm_group_label>Maintenance Phase: Mycophenolate mofetil</arm_group_label>
    <arm_group_label>Maintenance Phase: Azathioprine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female patients, 12-75 years of age;

          -  diagnosis of systemic lupus erythematosus;

          -  kidney biopsy within 6 months of study, with histological diagnosis of lupus
             nephritis;

          -  laboratory evidence of active nephritis.

        Exclusion Criteria:

          -  continuous dialysis starting &gt;2 weeks before randomization into induction phase,
             and/or with an anticipated duration of &gt;8 weeks;

          -  previous or planned kidney transplant;

          -  other clinically significant active medical conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0358</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7280</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425DQK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Córdoba</city>
        <zip>5016</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Isidro</city>
        <zip>B1602BPPD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucuman</city>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <zip>SA 5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodville</city>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>04039-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sorocaba</city>
        <zip>18030-210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8Z 7X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangdong</city>
        <zip>510008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jiangsu</city>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Bramstedt</city>
        <zip>24576</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heraklion</city>
        <zip>71500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pécs</city>
        <zip>7632</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <zip>2724</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brescia</city>
        <zip>25125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merida</city>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Luis Potosi</city>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>W12 OHS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>WIT 4NJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Costa Rica</country>
    <country>Malaysia</country>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2006</study_first_submitted>
  <study_first_submitted_qc>September 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2006</study_first_posted>
  <results_first_submitted>August 11, 2011</results_first_submitted>
  <results_first_submitted_qc>October 31, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2011</results_first_posted>
  <last_update_submitted>October 31, 2011</last_update_submitted>
  <last_update_submitted_qc>October 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The induction phase was a prospective, randomized, open-label, active controlled, parallel group, international multicenter, 2-arm comparison study of MMF versus IVC in inducing a response in patients with Lupus nephritis. Responders in the induction phase were re-randomized into a double-blind, double-dummy, active controlled Maintenance Phase.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Induction Phase: Cyclophosphamide</title>
          <description>Participants received monthly intravenous infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.</description>
        </group>
        <group group_id="P2">
          <title>Induction Phase: Mycophenolate Mofetil</title>
          <description>Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24-weeks of the Induction Phase.</description>
        </group>
        <group group_id="P3">
          <title>Maintenance Phase: Mycophenolate Mofetil</title>
          <description>Participants who responded to Induction Phase treatment received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
        </group>
        <group group_id="P4">
          <title>Maintenance Phase: Azathioprine</title>
          <description>Participants who responded to Induction Phase treatment received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="185">Intent-To-Treat</participants>
                <participants group_id="P2" count="185">Intent-To-Treat</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="150"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Deterioration/serum creatinine</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dose reduction of MMF &lt; 2 g/day for 14 d</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason for withdrawal is not noted</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="116"/>
                <participants group_id="P4" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study medication stopped &gt; 14 days</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Induction Phase: Cyclophosphamide</title>
          <description>Participants received monthly intravenous infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.</description>
        </group>
        <group group_id="B2">
          <title>Induction Phase: Mycophenolate Mofetil</title>
          <description>Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24-weeks of the Induction Phase.</description>
        </group>
        <group group_id="B3">
          <title>Maintenance Phase: Mycophenolate Mofetil</title>
          <description>Participants who responded to Induction Phase treatment received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
        </group>
        <group group_id="B4">
          <title>Maintenance Phase: Azathioprine</title>
          <description>Participants who responded to Induction Phase treatment received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="185"/>
            <count group_id="B2" value="185"/>
            <count group_id="B3" value="116"/>
            <count group_id="B4" value="111"/>
            <count group_id="B5" value="597"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Induction Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.3" spread="10.25"/>
                    <measurement group_id="B2" value="32.4" spread="11.7"/>
                    <measurement group_id="B3" value="NA">Did not participate in the Induction Phase. Please see Maintenance Phase.</measurement>
                    <measurement group_id="B4" value="NA">Did not participate in the Induction Phase. Please see Maintenance Phase.</measurement>
                    <measurement group_id="B5" value="31.9" spread="10.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Did not participate in the Maintenance Phase. Please see Induction Phase.</measurement>
                    <measurement group_id="B2" value="NA">Did not participate in the Maintenance Phase. Please see Induction Phase.</measurement>
                    <measurement group_id="B3" value="31.8" spread="10.59"/>
                    <measurement group_id="B4" value="31.0" spread="10.77"/>
                    <measurement group_id="B5" value="31.4" spread="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Induction Phase - Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induction Phase - Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance Phase - Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="96"/>
                    <measurement group_id="B5" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance Phase - Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Induction Phase: Number of Patients Showing Treatment Response</title>
        <description>Treatment response was adjudicated by a blinded clinical endpoints committee (CEC) and defined as: a) Decrease in proteinuria, defined as a decrease in the urine protein to creatinine ratio (UPCr) to &lt;3 in subjects with baseline proteinuria ≥3 UPCr or a decrease in the UPCr by ≥50% in subjects with proteinuria &lt;3 UPCr at Baseline, and b) Stabilization of serum creatinine or improvement. UPCr were derived from the 24 hour urine collection. Patients who did not show a treatment response at Week 24 or who withdrew earlier than Week 24 were considered non-responders.</description>
        <time_frame>24 weeks</time_frame>
        <population>Analysis population was intent to treat which comprised all subjects who were randomized into the study and had at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Cyclophosphamide</title>
            <description>Participants received monthly intravenous infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.</description>
          </group>
          <group group_id="O2">
            <title>Mycophenolate Mofetil</title>
            <description>Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24-weeks of the Induction Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Phase: Number of Patients Showing Treatment Response</title>
          <description>Treatment response was adjudicated by a blinded clinical endpoints committee (CEC) and defined as: a) Decrease in proteinuria, defined as a decrease in the urine protein to creatinine ratio (UPCr) to &lt;3 in subjects with baseline proteinuria ≥3 UPCr or a decrease in the UPCr by ≥50% in subjects with proteinuria &lt;3 UPCr at Baseline, and b) Stabilization of serum creatinine or improvement. UPCr were derived from the 24 hour urine collection. Patients who did not show a treatment response at Week 24 or who withdrew earlier than Week 24 were considered non-responders.</description>
          <population>Analysis population was intent to treat which comprised all subjects who were randomized into the study and had at least one post-baseline efficacy assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.478</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Covariates included Treatment, Race, Geographical Region, and WHO Lupus Nephritis Class V and specified interaction terms.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maintenance Phase: Kaplan-Meier Estimates of Percentage of Participants Treatment Failure Free, by Time Interval</title>
        <description>Treatment Failure was adjudicated by a clinical endpoints committee and was defined as the time to the earliest occurrence of any one of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or a requirement for rescue therapy for exacerbation or deterioration of Lupus nephritis. Kaplan-Meier survival curves were estimated from the observed time to treatment failure for each patient. The data presented are the percentage of participants who were treatment-failure free at each time interval as estimated by Kaplan-Meier.</description>
        <time_frame>From the start of the Maintenance Phase to Month 36</time_frame>
        <population>Intent to treat analysis population which consisted of all subjects who were randomized to the maintenance phase of the study and had at least 1 maintenance efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil</title>
            <description>Participants who responded to Induction Phase treatment received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
          </group>
          <group group_id="O2">
            <title>Azathioprine</title>
            <description>Participants who responded to Induction Phase treatment received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Phase: Kaplan-Meier Estimates of Percentage of Participants Treatment Failure Free, by Time Interval</title>
          <description>Treatment Failure was adjudicated by a clinical endpoints committee and was defined as the time to the earliest occurrence of any one of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or a requirement for rescue therapy for exacerbation or deterioration of Lupus nephritis. Kaplan-Meier survival curves were estimated from the observed time to treatment failure for each patient. The data presented are the percentage of participants who were treatment-failure free at each time interval as estimated by Kaplan-Meier.</description>
          <population>Intent to treat analysis population which consisted of all subjects who were randomized to the maintenance phase of the study and had at least 1 maintenance efficacy assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Maintenance Phase to Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2"/>
                    <measurement group_id="O2" value="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 to Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7"/>
                    <measurement group_id="O2" value="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 to Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9"/>
                    <measurement group_id="O2" value="86.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 to Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0"/>
                    <measurement group_id="O2" value="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 to Month 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0"/>
                    <measurement group_id="O2" value="77.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 to Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9"/>
                    <measurement group_id="O2" value="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 to Month 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9"/>
                    <measurement group_id="O2" value="70.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 to Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9"/>
                    <measurement group_id="O2" value="68.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 to Month 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8"/>
                    <measurement group_id="O2" value="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 27 to Month 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8"/>
                    <measurement group_id="O2" value="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 to Month 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7"/>
                    <measurement group_id="O2" value="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33 to Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7"/>
                    <measurement group_id="O2" value="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The difference in Kaplan-Meier survival curves between treatment groups (MMF−AZA) was assessed using a log-rank test, which is a non-parametric test to compare the survival distributions of two groups commonly used to analyze time-to-event endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>Testing at the alpha=0.05 level was applied with no adjustments made for multiplicity.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Phase: Number of Participants Achieving Complete Remission</title>
        <description>Number of participants achieving complete remission as defined by return to normal serum creatinine, proteinuria ≤500 mg/24 hours and an inactive urinary sediment (absence of red blood cells, white blood cells or cellular or granular casts) after 24 weeks.</description>
        <time_frame>24 weeks</time_frame>
        <population>Analysis population was intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Cyclophosphamide</title>
            <description>Participants received monthly intravenous infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.</description>
          </group>
          <group group_id="O2">
            <title>Mycophenolate Mofetil</title>
            <description>Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24-weeks of the Induction Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Phase: Number of Participants Achieving Complete Remission</title>
          <description>Number of participants achieving complete remission as defined by return to normal serum creatinine, proteinuria ≤500 mg/24 hours and an inactive urinary sediment (absence of red blood cells, white blood cells or cellular or granular casts) after 24 weeks.</description>
          <population>Analysis population was intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Remission - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Remission - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Phase: Change From Baseline to Week 24 in Serum Creatinine</title>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Analysis population was intent to treat. The analysis included only those patients for whom data was available at both time points, as indicated by &quot;n&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Cyclophosphamide</title>
            <description>Participants received monthly intravenous infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.</description>
          </group>
          <group group_id="O2">
            <title>Mycophenolate Mofetil</title>
            <description>Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24-weeks of the Induction Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Phase: Change From Baseline to Week 24 in Serum Creatinine</title>
          <population>Analysis population was intent to treat. The analysis included only those patients for whom data was available at both time points, as indicated by &quot;n&quot;.</population>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [n= 184, 185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" spread="56.88"/>
                    <measurement group_id="O2" value="108.6" spread="97.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 [n= 155, 151]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5" spread="56.26"/>
                    <measurement group_id="O2" value="77.6" spread="35.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 24 [n= 154, 151]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="45.96"/>
                    <measurement group_id="O2" value="-18.9" spread="59.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Phase: Change From Baseline to Week 24 in 24-hour Urine Protein</title>
        <description>24-hour urine protein was measured at Baseline and Week 24.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Analysis population was intent to treat. The analysis included only those patients for whom data was available at both time points, as indicated by &quot;n&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Cyclophosphamide</title>
            <description>Participants received monthly intravenous infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.</description>
          </group>
          <group group_id="O2">
            <title>Mycophenolate Mofetil</title>
            <description>Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24-weeks of the Induction Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Phase: Change From Baseline to Week 24 in 24-hour Urine Protein</title>
          <description>24-hour urine protein was measured at Baseline and Week 24.</description>
          <population>Analysis population was intent to treat. The analysis included only those patients for whom data was available at both time points, as indicated by &quot;n&quot;.</population>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [n=180, 180]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4451.4" spread="3506.59"/>
                    <measurement group_id="O2" value="4208.9" spread="3347.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 [n= 150, 144]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1831.6" spread="2413.84"/>
                    <measurement group_id="O2" value="1599.0" spread="2165.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 24 [n= 146, 142]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2513.7" spread="3223.68"/>
                    <measurement group_id="O2" value="-2510.6" spread="3132.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Phase: Change From Baseline to Week 24 in Serum Albumin</title>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Analysis population was intent to treat. The analysis included only those patients for whom data was available at both time points, as indicated by &quot;n&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Cyclophosphamide</title>
            <description>Participants received monthly intravenous infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.</description>
          </group>
          <group group_id="O2">
            <title>Mycophenolate Mofetil</title>
            <description>Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24-weeks of the Induction Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Phase: Change From Baseline to Week 24 in Serum Albumin</title>
          <population>Analysis population was intent to treat. The analysis included only those patients for whom data was available at both time points, as indicated by &quot;n&quot;.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [n=184, 185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="6.98"/>
                    <measurement group_id="O2" value="30.5" spread="6.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 [n=155, 151]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" spread="6.16"/>
                    <measurement group_id="O2" value="38.4" spread="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 24 [n=154, 151]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="6.77"/>
                    <measurement group_id="O2" value="7.5" spread="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Phase: Change in Renal British Isles Lupus Assessment Group (BILAG) Score</title>
        <description>BILAG indices provide a scoring system for the assessment of lupus disease activity in terms of the need for steroid treatment in 8 organs/systems. Eighty-six items were scored resulting in a classification of A (severe activity), B (moderate activity), C (mild activity), D (no current activity) and E (no activity ever observed) for each organ system. The BILAG individual system summaries were calculated by a program supplied by ADS-Limathon (Sheffield, UK).
The score at baseline was compared to the score at the 24 week endpoint for each treatment group, reported here for the renal system.</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis population was intent to treat. The endpoint was defined using the last observation carried forward approach. If no post-Baseline value was available, endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Cyclophosphamide</title>
            <description>Participants received monthly intravenous infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.</description>
          </group>
          <group group_id="O2">
            <title>Mycophenolate Mofetil</title>
            <description>Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24-weeks of the Induction Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Phase: Change in Renal British Isles Lupus Assessment Group (BILAG) Score</title>
          <description>BILAG indices provide a scoring system for the assessment of lupus disease activity in terms of the need for steroid treatment in 8 organs/systems. Eighty-six items were scored resulting in a classification of A (severe activity), B (moderate activity), C (mild activity), D (no current activity) and E (no activity ever observed) for each organ system. The BILAG individual system summaries were calculated by a program supplied by ADS-Limathon (Sheffield, UK).
The score at baseline was compared to the score at the 24 week endpoint for each treatment group, reported here for the renal system.</description>
          <population>Analysis population was intent to treat. The endpoint was defined using the last observation carried forward approach. If no post-Baseline value was available, endpoint was considered missing.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Shift from Baseline=A to 24 Week Endpoint=A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1"/>
                    <measurement group_id="O2" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=A to 24 Week Endpoint=B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8"/>
                    <measurement group_id="O2" value="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=A to 24 Week Endpoint=C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9"/>
                    <measurement group_id="O2" value="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=A to 24 Week Endpoint=D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=B to 24 Week Endpoint=A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=B to 24 Week Endpoint=B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=B to 24 Week Endpoint=C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=B to 24 Week Endpoint=D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=C to 24 Week Endpoint=A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=C to 24 Week Endpoint=B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=C to 24 Week Endpoint=C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=C to 24 Week Endpoint=D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=D to 24 Week Endpoint=A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=D to 24 Week Endpoint=B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=D to 24 Week Endpoint=C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shift from Baseline=D to 24 Week Endpoint=D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Phase: Change From Baseline in Short-Form Health Survey (SF-36) Domain and Component Scores</title>
        <description>The SF-36 is a 36 item quality of life questionnaire. The short-form version has eleven questions that permit the participant to rate how they feel that particular day. The SF-36 consists of eight scaled scores and two component scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 score with the higher scores indicating better quality of life.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>This analysis population is intention to treat. The analysis included only those patients for whom data was available at both time points, as indicated by &quot;n&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Cyclophosphamide</title>
            <description>Participants received monthly intravenous infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.</description>
          </group>
          <group group_id="O2">
            <title>Mycophenolate Mofetil</title>
            <description>Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24-weeks of the Induction Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Phase: Change From Baseline in Short-Form Health Survey (SF-36) Domain and Component Scores</title>
          <description>The SF-36 is a 36 item quality of life questionnaire. The short-form version has eleven questions that permit the participant to rate how they feel that particular day. The SF-36 consists of eight scaled scores and two component scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 score with the higher scores indicating better quality of life.</description>
          <population>This analysis population is intention to treat. The analysis included only those patients for whom data was available at both time points, as indicated by &quot;n&quot;.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component Summary [n=139, 137]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="8.74"/>
                    <measurement group_id="O2" value="5.2" spread="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Summary [n=139, 137]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="11.39"/>
                    <measurement group_id="O2" value="6.7" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain Score [n=141, 137]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="25.85"/>
                    <measurement group_id="O2" value="13.4" spread="24.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health Score [n=139, 137]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="20.90"/>
                    <measurement group_id="O2" value="9.1" spread="19.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health Score [n=141, 137]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="19.47"/>
                    <measurement group_id="O2" value="9.3" spread="18.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning Score [n=141, 137]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="24.63"/>
                    <measurement group_id="O2" value="11.6" spread="23.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Emotional Score [n=141, 137]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="46.71"/>
                    <measurement group_id="O2" value="23.4" spread="44.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical Score [n=141, 137]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" spread="47.65"/>
                    <measurement group_id="O2" value="28.6" spread="48.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Function Score [n=141, 137]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="29.26"/>
                    <measurement group_id="O2" value="17.7" spread="28.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality Score [n=141, 137]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="20.68"/>
                    <measurement group_id="O2" value="14.2" spread="23.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Deaths</title>
        <description>Treatment Failure was adjudicated by a clinical endpoints committee (CEC) and was defined as the time to the earliest occurrence of any one of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or a requirement for rescue therapy for exacerbation or deterioration of Lupus nephritis (LN).</description>
        <time_frame>From the start of the Maintenance Phase to Month 36</time_frame>
        <population>Maintenance Phase intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil (MMF)</title>
            <description>Mycophenolate mofetil (MMF) 1.0 g orally twice a day + Placebo to Azathioprine orally once a day + Corticosteroid for 36 months</description>
          </group>
          <group group_id="O2">
            <title>Azathioprine (AZA)</title>
            <description>Azathioprine (AZA) 2 mg/kg/day orally once a day + Placebo to MMF orally twice a day + Corticosteroid for 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Deaths</title>
          <description>Treatment Failure was adjudicated by a clinical endpoints committee (CEC) and was defined as the time to the earliest occurrence of any one of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or a requirement for rescue therapy for exacerbation or deterioration of Lupus nephritis (LN).</description>
          <population>Maintenance Phase intent to treat population.</population>
          <units>Deaths</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Participants With End-stage Renal Disease (ESRD)</title>
        <description>Time to treatment failure, adjudicated by the Clinical Endpoints Committee (CEC), was defined as any 1 the following: death, ESRD, sustained doubling of serum creatinine, renal flare (proteinuric or nephritic), or requirement for rescue therapy to treat deterioration or exacerbation of Lupus nephritis. ESRD is defined as progression to chronic hemodialysis or renal transplant.</description>
        <time_frame>From the start of the Maintenance Phase to Month 36</time_frame>
        <population>Maintenance Phase intent to treat population. The analysis includes all event data, regardless of whether or not the event was the earliest Clinical Endpoints Committee-adjudicated reason for treatment failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil (MMF)</title>
            <description>Mycophenolate mofetil (MMF) 1.0 g twice daily (BID) along with placebo matching AZA (2.0 mg/kg/day), plus corticosteroid, until 36 months of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Azathioprine (AZA)</title>
            <description>Azathioprine (AZA) 2.0 mg/kg/day along with placebo matching MMF (1.0 g BID), plus corticosteroid for 36 months of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Participants With End-stage Renal Disease (ESRD)</title>
          <description>Time to treatment failure, adjudicated by the Clinical Endpoints Committee (CEC), was defined as any 1 the following: death, ESRD, sustained doubling of serum creatinine, renal flare (proteinuric or nephritic), or requirement for rescue therapy to treat deterioration or exacerbation of Lupus nephritis. ESRD is defined as progression to chronic hemodialysis or renal transplant.</description>
          <population>Maintenance Phase intent to treat population. The analysis includes all event data, regardless of whether or not the event was the earliest Clinical Endpoints Committee-adjudicated reason for treatment failure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Participants With Sustained Doubling of Serum Creatinine</title>
        <description>Sustained doubling of serum creatinine concentration is defined as the first serum creatinine value that is twice the mean of the lowest 2 values from screening to end of induction, as confirmed by a second serum creatinine value obtained at least 4 weeks after the initial doubling.</description>
        <time_frame>From the start of the Maintenance Phase to Month 36</time_frame>
        <population>Maintenance Phase intent to treat population. The analysis includes all event data, regardless of whether or not the event was the earliest Clinical Endpoints Committee-adjudicated reason for treatment failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil</title>
            <description>Participants who responded to Induction Phase treatment received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
          </group>
          <group group_id="O2">
            <title>Azathioprine</title>
            <description>Participants who responded to Induction Phase treatment received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Participants With Sustained Doubling of Serum Creatinine</title>
          <description>Sustained doubling of serum creatinine concentration is defined as the first serum creatinine value that is twice the mean of the lowest 2 values from screening to end of induction, as confirmed by a second serum creatinine value obtained at least 4 weeks after the initial doubling.</description>
          <population>Maintenance Phase intent to treat population. The analysis includes all event data, regardless of whether or not the event was the earliest Clinical Endpoints Committee-adjudicated reason for treatment failure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Phase: Events Contributing to the Primary Endpoint: Kaplan-Meier Estimates of Percentage of Participants Renal Flare Free, by Time Interval</title>
        <description>A proteinuric flare is defined as a doubling of the urine protein:creatinine ratio, and proteinuria ≥1 g/24 h in patients with urine protein ≤0.5 g/24 h at the end of the induction phase, or proteinuria ≥2 g/24 h if urine protein was &gt;0.5 g/24 h at the end of the induction phase. A nephritic flare is defined as a 25% increase in serum creatinine accompanied by 1 or more of the following: (a) simultaneous doubling of the proteinuria reaching a minimum of 2 g/24 h (b) new/increased hematuria or (c) the appearance of cellular casts. All flares were adjudicated by a clinical endpoints committee.</description>
        <time_frame>From the start of the Maintenance Phase to Month 36</time_frame>
        <population>Maintenance Phase intent to treat population. The analysis includes all event data, regardless of whether or not the event was the earliest Clinical Endpoints Committee-adjudicated reason for treatment failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil</title>
            <description>Participants who responded to Induction Phase treatment received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
          </group>
          <group group_id="O2">
            <title>Azathioprine</title>
            <description>Participants who responded to Induction Phase treatment received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Phase: Events Contributing to the Primary Endpoint: Kaplan-Meier Estimates of Percentage of Participants Renal Flare Free, by Time Interval</title>
          <description>A proteinuric flare is defined as a doubling of the urine protein:creatinine ratio, and proteinuria ≥1 g/24 h in patients with urine protein ≤0.5 g/24 h at the end of the induction phase, or proteinuria ≥2 g/24 h if urine protein was &gt;0.5 g/24 h at the end of the induction phase. A nephritic flare is defined as a 25% increase in serum creatinine accompanied by 1 or more of the following: (a) simultaneous doubling of the proteinuria reaching a minimum of 2 g/24 h (b) new/increased hematuria or (c) the appearance of cellular casts. All flares were adjudicated by a clinical endpoints committee.</description>
          <population>Maintenance Phase intent to treat population. The analysis includes all event data, regardless of whether or not the event was the earliest Clinical Endpoints Committee-adjudicated reason for treatment failure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Maintenance Phase to Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2"/>
                    <measurement group_id="O2" value="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 to Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6"/>
                    <measurement group_id="O2" value="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 to Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8"/>
                    <measurement group_id="O2" value="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 to Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8"/>
                    <measurement group_id="O2" value="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 to Month 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8"/>
                    <measurement group_id="O2" value="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 to Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8"/>
                    <measurement group_id="O2" value="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 to Month 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8"/>
                    <measurement group_id="O2" value="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 to Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8"/>
                    <measurement group_id="O2" value="75.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 to Month 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8"/>
                    <measurement group_id="O2" value="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 27 to Month 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8"/>
                    <measurement group_id="O2" value="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 to Month 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.6"/>
                    <measurement group_id="O2" value="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33 to Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.6"/>
                    <measurement group_id="O2" value="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Phase: Events Contributing to the Primary Endpoint: Kaplan-Meier Estimates of Percentage of Participants Not Receiving Rescue Therapy</title>
        <description>The primary efficacy parameter was the time to treatment failure, adjudicated by the Clinical Endpoints Committee (CEC), defined as any of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or requirement for rescue therapy to treat deterioration or exacerbation of Lupus nephritis. Kaplan-Meier survival curves were estimated from the observed time to rescue treatment for each patient. The data presented are the percentage of participants who were rescue treatment free at each time interval as estimated by Kaplan-Meier.</description>
        <time_frame>From the start of the Maintenance Phase to Month 36</time_frame>
        <population>Maintenance Phase intent to treat population. The analysis includes all event data, regardless of whether or not the event was the earliest Clinical Endpoints Committee-adjudicated reason for treatment failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil</title>
            <description>Participants who responded to Induction Phase treatment received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
          </group>
          <group group_id="O2">
            <title>Azathioprine</title>
            <description>Participants who responded to Induction Phase treatment received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Phase: Events Contributing to the Primary Endpoint: Kaplan-Meier Estimates of Percentage of Participants Not Receiving Rescue Therapy</title>
          <description>The primary efficacy parameter was the time to treatment failure, adjudicated by the Clinical Endpoints Committee (CEC), defined as any of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or requirement for rescue therapy to treat deterioration or exacerbation of Lupus nephritis. Kaplan-Meier survival curves were estimated from the observed time to rescue treatment for each patient. The data presented are the percentage of participants who were rescue treatment free at each time interval as estimated by Kaplan-Meier.</description>
          <population>Maintenance Phase intent to treat population. The analysis includes all event data, regardless of whether or not the event was the earliest Clinical Endpoints Committee-adjudicated reason for treatment failure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Maintenance Phase to Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 to Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2"/>
                    <measurement group_id="O2" value="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 to Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2"/>
                    <measurement group_id="O2" value="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 to Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2"/>
                    <measurement group_id="O2" value="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 to Month 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2"/>
                    <measurement group_id="O2" value="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 to Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2"/>
                    <measurement group_id="O2" value="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 to Month 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1"/>
                    <measurement group_id="O2" value="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 to Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9"/>
                    <measurement group_id="O2" value="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 to Month 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8"/>
                    <measurement group_id="O2" value="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 27 to Month 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8"/>
                    <measurement group_id="O2" value="80.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 to Month 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8"/>
                    <measurement group_id="O2" value="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33 to Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8"/>
                    <measurement group_id="O2" value="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Phase: Participants With Major Extra-renal Flare</title>
        <description>A major extra-renal flare is defined as a British Isles Lupus Assessment Group (BILAG) Score category A in one extrarenal organ or three organs with concurrent category B scores. BILAG indices provide a scoring system for the assessment of lupus disease activity in terms of the need for steroid treatment in 8 organs/systems. Eighty-six items were scored resulting in a classification of A (severe activity), B (moderate activity), C (mild activity), D (no current activity) and E (no activity ever observed) for each organ system.</description>
        <time_frame>From the start of the Maintenance Phase to Month 36</time_frame>
        <population>Maintenance Phase intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Mycophenolate Mofetil</title>
            <description>Participants who responded to Induction Phase treatment received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
          </group>
          <group group_id="O2">
            <title>Azathioprine</title>
            <description>Participants who responded to Induction Phase treatment received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Phase: Participants With Major Extra-renal Flare</title>
          <description>A major extra-renal flare is defined as a British Isles Lupus Assessment Group (BILAG) Score category A in one extrarenal organ or three organs with concurrent category B scores. BILAG indices provide a scoring system for the assessment of lupus disease activity in terms of the need for steroid treatment in 8 organs/systems. Eighty-six items were scored resulting in a classification of A (severe activity), B (moderate activity), C (mild activity), D (no current activity) and E (no activity ever observed) for each organ system.</description>
          <population>Maintenance Phase intent to treat population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were monitored from the time of informed consent throughout the course of the study (up to 42 months).</time_frame>
      <desc>The induction and maintenance phases were analyzed separately. All safety analyses are based on the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Induction Phase: Cyclophosphamide</title>
          <description>Participants received monthly intravenous infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.</description>
        </group>
        <group group_id="E2">
          <title>Induction Phase: Mycophenolate Mofetil</title>
          <description>Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24-weeks of the Induction Phase.</description>
        </group>
        <group group_id="E3">
          <title>Maintenance Phase: Mycophenolate Mofetil</title>
          <description>Participants who responded to Induction Phase treatment received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
        </group>
        <group group_id="E4">
          <title>Maintenance Phase: Azathioprine</title>
          <description>Participants who responded to Induction Phase treatment received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Acinetobacter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Tuberculosis gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Retroperitoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Meningitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Subacute endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Peridiverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Genitourinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Traumatic hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Biopsy kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Uterine carcinoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lupus encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Superior sagittal sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abnormal behavior</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lupus nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Ovarian hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lupus pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Venous stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="108" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Lupus nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Butterfly rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>For many of the Maintenance Phase Outcomes, the total number of events precluded a meaningful time to event statistical analysis, therefore, only events numbers are reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffman-LaRoche</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

